TRASTUZUMAB DERUXTECAN
ESR-21-21447
Phase 2 small_molecule active
Quick answer
TRASTUZUMAB DERUXTECAN for metastatic HER2-positive breast cancer patients is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- metastatic HER2-positive breast cancer patients
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active